It has been proposed that alpha emitting 212Bi (t1/2 = 60 min) coupled to tumor-specific antibodies may be a useful radiotherapeutic agent. However, since Bi can accumulate in the kidney, it is necessary to characterize the factors influencing localization of Bi within this tissue in order to evaluate the potential for radiation damage to the renal system. In this study, the localization of Bi radiotracers was determined in kidneys of rats previously exposed and not exposed to mumole quantities of Bi. Following repeated injection of Bi (4 x 14 mumols (3 mg Bi)/kg bw) the element accumulated mainly in the kidney followed by liver, spleen, pancreas, bone, and brain. Kidney copper and liver zinc concentrations were higher in Bi-exposed rats than in non-exposed rats. Within the cytosol, in Bi-exposed rats, Bi radiotracer in the kidney was associated with a metallothionein-like protein (Mt). In contrast, non-exposed rats contained no detectable metallothionein-like proteins in the kidney and the Bi tracer was associated with the hemoglobin fraction of the cell. Thus, when Bi is administered in tracer quantities such as that incorporated for use as a radiopharmaceutical, no induction of, and association with, metallothionein-like proteins should occur. These results suggest that the potential nephrotic effects of 212Bi will be influenced by the individual's previous exposure to Bi-containing drugs, or other metallothionein-inducing insults.